An update on GM-CSF and its potential role in melanoma management.

摘要: GM-CSF drives the differentiation of granulocytes and monocyte/macrophages from hematopoietic stem cell progenitors. It is required for differentiating monocytes into dendritic cells (DC). Although approved recovery granulocytes/monocytes in patients receiving chemotherapy, G-CSF preferred. Enthusiasm monotherapy as a melanoma treatment was dampened by two large randomized trials. has been injected tumors many years, efficacy this not tested. There strong rationale vaccine adjuvant, but it appears benefit only strategies that directly involve DCs, such intratumor talimogene laherparepvec vaccines which DCs are loaded with antigen ex vivo admixed GM-CSF.